These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 32615660)

  • 21. Targeted knockdown of Tim3 by short hairpin RNAs improves the function of anti-mesothelin CAR T cells.
    Jafarzadeh L; Masoumi E; Mirzaei HR; Alishah K; Fallah-Mehrjardi K; Khakpoor-Koosheh M; Rostamian H; Noorbakhsh F; Hadjati J
    Mol Immunol; 2021 Nov; 139():1-9. PubMed ID: 34450537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.
    Chen J; Hu J; Gu L; Ji F; Zhang F; Zhang M; Li J; Chen Z; Jiang L; Zhang Y; Shi R; Ma L; Jia S; Zhang Y; Zhang Q; Liang J; Yao S; Hu Z; Guo Z
    Cancer Immunol Immunother; 2023 Feb; 72(2):409-425. PubMed ID: 35925286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells.
    Tokatlian T; Asuelime GE; Mock JY; DiAndreth B; Sharma S; Toledo Warshaviak D; Daris ME; Bolanos K; Luna BL; Naradikian MS; Deshmukh K; Hamburger AE; Kamb A
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy.
    Zhang E; Yang P; Gu J; Wu H; Chi X; Liu C; Wang Y; Xue J; Qi W; Sun Q; Zhang S; Hu J; Xu H
    J Hematol Oncol; 2018 Aug; 11(1):102. PubMed ID: 30103775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors.
    Ding J; Guyette S; Schrand B; Geirut J; Horton H; Guo G; Delgoffe G; Menk A; Baeuerle PA; Hofmeister R; Tighe R
    Oncoimmunology; 2023; 12(1):2182058. PubMed ID: 36875551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer.
    Zhao R; Cui Y; Zheng Y; Li S; Lv J; Wu Q; Long Y; Wang S; Yao Y; Wei W; Yang J; Wang BC; Zhang Z; Zeng H; Li Y; Li P
    Front Immunol; 2021; 12():660488. PubMed ID: 34326835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
    Le Q; Castro S; Tang T; Loeb AM; Hylkema T; McKay CN; Perkins L; Srivastava S; Call L; Smith J; Leonti A; Ries R; Pardo L; Loken MR; Correnti C; Fiorenza S; Turtle CJ; Riddell S; Tarlock K; Meshinchi S
    Clin Cancer Res; 2021 Oct; 27(20):5718-5730. PubMed ID: 34380639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression.
    Jiang W; Gu G; Zhang Y; Song Y; Shi M; Wang G; Li H; Tao T; Qin J; Li X; Jia H; Jiao F; Xu W; Huang X
    Pharmacol Res; 2023 Nov; 197():106942. PubMed ID: 37775021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer.
    Cao B; Liu M; Huang J; Zhou J; Li J; Lian H; Huang W; Guo Y; Yang S; Lin L; Cai M; Zhi C; Wu J; Liang L; Hu Y; Hu H; He J; Liang B; Zhao Q; Zhu K
    Int J Biol Sci; 2021; 17(14):3850-3861. PubMed ID: 34671203
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
    Haas AR; Tanyi JL; O'Hara MH; Gladney WL; Lacey SF; Torigian DA; Soulen MC; Tian L; McGarvey M; Nelson AM; Farabaugh CS; Moon E; Levine BL; Melenhorst JJ; Plesa G; June CH; Albelda SM; Beatty GL
    Mol Ther; 2019 Nov; 27(11):1919-1929. PubMed ID: 31420241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope.
    Liu XF; Onda M; Schlomer J; Bassel L; Kozlov S; Tai CH; Zhou Q; Liu W; Tsao HE; Hassan R; Ho M; Pastan I
    Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2317283121. PubMed ID: 38227666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice.
    Zhang Q; Liu G; Liu J; Yang M; Fu J; Liu G; Li D; Gu Z; Zhang L; Pan Y; Cui X; Wang L; Zhang L; Tian X
    Mol Ther Oncolytics; 2021 Mar; 20():556-568. PubMed ID: 33738341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer.
    Guo J; Zeng X; Zhu Y; Yang D; Zhao X
    J Transl Med; 2024 Apr; 22(1):367. PubMed ID: 38637885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.
    Anderson KG; Voillet V; Bates BM; Chiu EY; Burnett MG; Garcia NM; Oda SK; Morse CB; Stromnes IM; Drescher CW; Gottardo R; Greenberg PD
    Cancer Immunol Res; 2019 Sep; 7(9):1412-1425. PubMed ID: 31337659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mesothelin-Specific CAR T Cells Target Ovarian Cancer.
    Schoutrop E; El-Serafi I; Poiret T; Zhao Y; Gultekin O; He R; Moyano-Galceran L; Carlson JW; Lehti K; Hassan M; Magalhaes I; Mattsson J
    Cancer Res; 2021 Jun; 81(11):3022-3035. PubMed ID: 33795251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor.
    Zhang Z; Jiang D; Yang H; He Z; Liu X; Qin W; Li L; Wang C; Li Y; Li H; Xu H; Jin H; Qian Q
    Cell Death Dis; 2019 Jun; 10(7):476. PubMed ID: 31209210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
    Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
    Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.
    Lanitis E; Poussin M; Hagemann IS; Coukos G; Sandaltzopoulos R; Scholler N; Powell DJ
    Mol Ther; 2012 Mar; 20(3):633-43. PubMed ID: 22127019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.